Improving EGFR kinase inhibitor design for the targeted treatment of lung cancer.

摘要: With over 174,000 new cases of lung cancer being diagnosed in the United States each year novel chemotherapy treatments with efficacy towards both small-cell and non-small cell carcinoma is interest to increase survival rate patients.1,2 Historically pharmaceutical have been based on surgery, radiation therapy, broad spectrum chemotherapies. New research now focused targeted approaches that seek either inhibit specific proteins necessary for cellular proliferation or initiate apoptosis removal cancerous cells. The Epithelial Growth Factor (EGF) its Receptor (EGFR) EGFR protein initiates growth has found be overexpressed cells which makes it an effective approach treatment.3-5 Specifically, this determined structural blockade tyrosine kinase receptor as a way propagation use FDA approved drugs. 22 crystal structures were docked using IGEMDock 714 drugs determine correlation most binders. Structural similarities wih vROCS partition coefficient was DRAGON program. This data cluster approximately 25 preferentially bind treatments. work will used engineering improved inhibitors.